Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

  • There is currently no data for ROQ

Corporate Update

19 Jul 2021 07:00

RNS Number : 5009F
Roquefort Investments PLC
19 July 2021
 

19 July 2021

 

roquefort investments PLC

("Roquefort Investments" or the "Company")‎

 

Corporate Update

 

Roquefort Investments plc, an investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, provides the following corporate update.

 

Further to the admission of the Company's shares to the Official List by way of a standard listing and to trading on the London Stock Exchange in March 2021, the Company has been progressing the formal screening of various compelling opportunities in line with its stated objective of acquiring a biotechnology business that is in the "research" or "pre-clinical development" stage in the medical sector. Whilst the Company is at an early stage in such process, the Board is encouraged by the initial due diligence it has initiated.

The Company has not been negatively impacted by the ongoing COVID-19 pandemic and believes it will ultimately benefit from the increased market focus on the medical biotechnology industry in the current environment.

Roquefort Investment's business model is well tailored to the current climate in terms of maintaining low overheads to preserve cash, seeking early-stage established businesses in the medical biotechnology industry enabling a cost-effective entry point to compelling opportunities, and utilising the commercial and technical capabilities of its management team to progress opportunities internally.

 

Stephen West, Chairman of Roquefort Investments, commented:

"The current environment has undoubtedly led to more opportunities in the exciting biotechnology sector coming to our attention, which we have now high-graded in order to focus on the most compelling. These high-graded opportunities are fully consistent with our strategy and we are most encouraged by the progress we are making with our initial due diligence discussions. We hope to provide a more detailed update in due course as these discussions progress further and we have narrowed down our selection to an appropriate target."

Enquiries:

Roquefort Investments plc

Stephen West (Chairman)

+44 (0)20 3290 9339

Optiva Securities Limited (Broker)

Christian Dennis

+44 (0)20 3411 1881

 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

 

 

About Roquefort Investments

Roquefort Investments was formed as an investment company to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. It is envisaged that such acquisition or acquisitions will trigger a reverse takeover in accordance with the listing rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBGGDRRDBDGBL
Date   Source Headline
26th Mar 20261:00 pmRNS-RInvestor Presentation
26th Mar 202612:08 pmRNSResult of General Meeting
25th Mar 20267:00 amRNSLyramid SPA & MK Cell License Update
2nd Mar 20268:00 amRNSSchedule One - Roquefort Therapeutics PLC
2nd Mar 20267:00 amRNSProposed Acquisition and Fundraise of £8.5 million
25th Feb 20267:00 amRNSTransaction Update & Notice of Intention to Delist
15th Jan 20267:00 amRNS-RResearch Note Published
12th Dec 20257:00 amRNSClinical Trial & License Agreement Update
9th Dec 20257:00 amRNSConversion of CLNs
1st Dec 202510:35 amRNSEx-Entitlement Date - Unlisted RNV Shares
1st Dec 20257:00 amRNSDetermination of Record Date and Entitlement
25th Nov 20257:00 amRNSHolding(s) in Company
24th Nov 20257:00 amRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSExecuted License Agreement & Transaction Update
3rd Nov 20257:00 amRNSMK Cell Out-License & Lyramid SPA Update
16th Oct 20257:00 amRNSFundraise & Transaction Update
30th Sep 20257:00 amRNSInterim Results to 30 June 2025
24th Sep 20257:00 amRNS-RInvestor Presentation via Engage Investor
8th Sep 20257:00 amRNSProposed Acquisition of Clinical Stage Company
28th Aug 20257:00 amRNSLyramid SPA 2nd Extension & Carve Out
7th Jul 20257:00 amRNSDirector/PDMR Shareholding
30th Jun 20257:00 amRNSDirector/PDMR Shareholding
27th Jun 20257:00 amRNSLyramid SPA Extension
26th Jun 20251:00 pmRNSResults of AGM
13th Jun 20254:00 pmRNSIssue of Equity
2nd Jun 20257:00 amRNSNotice of Annual General Meeting
23rd May 20257:00 amRNSExtension of Convertible Loan Notes
13th May 20257:00 amRNSCorporate Update
30th Apr 20257:00 amRNSAnnual Report & Financial Statements - 31 Dec 2024
14th Mar 20257:00 amRNSPrivate Placing and Conversion of CLNs
10th Mar 20257:30 amRNSBoard Changes
10th Mar 20257:00 amRNSProposed Sale of Oncogeni Ltd
4th Mar 20257:00 amRNSUpdate on Sale of Lyramid
4th Feb 202510:58 amRNSDirector/PDMR Shareholding
3rd Feb 20257:00 amRNSShare Purchase Agreement Signed - Sale of Lyramid
2nd Jan 20257:00 amRNSProposed Sale of Midkine Portfolio
4th Dec 20244:00 pmRNSDirector Share Distribution
7th Nov 20247:00 amRNSConversion of Convertible Loan Notes
27th Sep 20247:00 amRNSInterim Results to 30 June 2024
23rd Sep 20247:00 amRNSGrant of Japan MK Cell Patent
19th Sep 20247:00 amRNSSTAT-6 siRNA Demonstrates Efficacy in Immunology
2nd Sep 20247:00 amRNSGrant of MK Cell Patent & Licencing Update
27th Jun 202412:46 pmRNSResults of AGM
20th Jun 20247:00 amRNSAppointment of Broker
4th Jun 20247:00 amRNSNotice of Annual General Meeting
23rd May 20247:05 amRNSIssue of Convertible Loan Notes & Board Changes
23rd May 20247:00 amRNSMidkine Antibody Licencing Deal
26th Apr 20247:00 amRNSAnnual Report & Financial Statements - 31 Dec 2023
5th Apr 20247:00 amRNSResponse to Share Price Movement
11th Mar 20247:00 amRNSPositive Results: Midkine mRNA and STAT-6 siRNA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.